Running Title: Non-invasive cardiac testing and two-year outcomes

- 1 Title: Increasing emergency department referral of chest pain patients for non-invasive cardiac
- 2 testing does not improve two-year clinical outcomes.
- 3 **Running title:** Non-invasive cardiac testing and two-year outcomes.
- 4 **Authors:** Dustin G. Mark, MD<sup>1,2,3</sup>; Jie Huang, PhD<sup>3</sup>; Dustin W. Ballard, MD, MBE<sup>3,4</sup>; David R.
- 5 Vinson, MD<sup>3,5</sup>; Jamal S. Rana, MD, PhD<sup>3,6</sup>; Dana R. Sax, MD, MPH<sup>1,3</sup>; Adina S. Rauchwerger,
- 6 MPH <sup>3</sup>; Mary E. Reed, DrPH <sup>3</sup> for the Kaiser Permanente CREST Network Investigators.

# 7 Affiliations:

- 8 1. Department of Emergency Medicine, Kaiser Permanente Medical Center, Oakland, California.
- 9 2. Department of Critical Care Medicine, Kaiser Permanente Medical Center, Oakland,
- 10 California.
- 11 3. Division of Research, Kaiser Permanente Northern California, Oakland, California.
- 4. Department of Emergency Medicine, Kaiser Permanente Medical Center, San Rafael,
   California.
- 14 5. Department of Emergency Medicine, Kaiser Permanente Medical Center, Roseville,
- 15 California.
- 16 6. Department of Cardiology, Kaiser Permanente Medical Center, Oakland, California.
- 17 Corresponding Author: Dustin Mark, MD. Department of Emergency Medicine, 3600 Broadway,
- 18 Oakland, CA, 94611. Email: Dustin.G.Mark@kp.org
- 19 **Financial support:** The Permanente Medical Group (TPMG) Community Health Research Grant
- 20 Word count (including Title Page, Abstract, Text, References, Tables and Figures Legends): 8052
- 21 Author contributions: study concept and design (DGM, JH, DWB, DRV, DRS, JSR, MER),
- 22 acquisition of the data (JH), analysis and interpretation of the data (DGM, JH, MER), drafting of
- 23 the manuscript (DGM, JS), critical revision of the manuscript for important intellectual content
- 24 (DGM, JH, DWB, DRV, DRS, JSR, ASR, MER), statistical expertise (JH, MER, DGM), and acquisition
- 25 of funding (DGM, JH, MER, ASR).
- 26 **COI Disclosure:** DGM, JH, DWB, DRV, DRS, JSR, ASR and MER report no conflicts of interest.

Running Title: Non-invasive cardiac testing and two-year outcomes

## 27 Abstract

- 28 Background: Non-invasive cardiac testing (NICT) has been associated with decreased long-term
- risks of major adverse cardiac events (MACE) among emergency department (ED) patients at
- 30 high coronary risk. It is unclear whether this association extends to patients without evidence of
- 31 myocardial injury on initial electrocardiogram and cardiac troponin testing.
- 32 Methods: Retrospective cohort study of patients presenting with chest pain between 2013-
- 33 2019 to 21 EDs within an integrated health care system, excluding patients with ST-elevation
- 34 myocardial infarction or myocardial injury by serum troponin testing. To account for
- 35 confounding by indication, we grouped patient encounters by the NICT referral rate of the
- 36 initially assigned emergency physician, relative to local peers within discrete time periods. The
- 37 primary outcome was MACE within two years. Secondary outcomes were coronary
- 38 revascularization and MACE inclusive of all-cause mortality (MACE-ALL). Associations between
- 39 NICT referral group (low, intermediate, or high) and outcomes were assessed using risk-
- 40 adjusted proportional hazards methods with censoring for competing events.
- 41 Results: Among 144,577 eligible patient encounters, 30-day NICT referral was 13.0%, 19.9% and
- 42 27.8% in low, intermediate, and high NICT referral groups, respectively, with good balance of
- 43 baseline covariates between groups. Compared with the low group, there was no significant
- 44 decrease in the adjusted hazard ratio (aHR) of MACE within the intermediate (aHR 1.08, 95% CI

45 1.02-1.14, adjusted p = 0.024) or high (aHR 1.05, 95% CI 0.99-1.11, adjusted p = 0.13) NICT

- 46 referral groups. Results were similar for MACE-ALL and coronary revascularization, as well as
- 47 subgroup analyses stratified by estimated risk (HEART score; 48.2% low-risk, 49.2% moderate-

48 risk, 2.7% high-risk).

49	Conclusion: Increased NICT referral was not associated with a decreased hazard of MACE within
50	two years following ED visits for chest pain without evidence of acute myocardial injury. These
51	findings further highlight the need for evidence-based guidance regarding appropriate use of
52	NICT in this population.
53	
54	Non-standard Abbreviations and Acronyms: BMI = body mass index; CAD = coronary artery
55	disease; ECG = electrocardiogram; ED = emergency department; HEART = history,
56	electrocardiogram, age, risk factors, troponin; KPNC = Kaiser Permanente Northern California;
57	LOQ = limit of quantitation; MACE = major adverse cardiac event; MACE-ALL = major adverse
58	cardiac event, including all-cause mortality; NICT = non-invasive cardiac test; STEMI = ST-
59	elevated myocardial infarction.
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	

70		
71	What	is Known:
72	•	In emergency department patients with chest pain but no evidence of acute myocardial
73		injury, referral for non-invasive cardiac testing is not associated with improved
74		outcomes within 6 to 12 months.
75	•	There is some evidence that non-invasive cardiac testing may improve longer-term
76		outcomes, especially among patients at moderate to high risk of coronary disease.
77		
70	\A/bat	the Study Adde
78	wnat	the Study Adds:
79	•	Higher non-invasive cardiac testing was not associated with improved outcomes within
80		two years following emergency department visits for chest pain, absent evidence of
81		acute myocardial injury.
82	•	This finding was most evident among patients at low to moderate predicted coronary
83		risk.
84		
85		
60		
86		
87		
88		
89		

Running Title: Non-invasive cardiac testing and two-year outcomes

# 90 Introduction

Chest pain is a leading reason for emergency department (ED) visits in the U.S., with upwards of 91 7 million patients evaluated annually.<sup>1</sup> Prior to 2021, American Heart Association/American 92 College of Cardiology guidelines recommended functional or anatomic non-invasive cardiac 93 94 testing (NICT) of ED patients with chest pain and possible acute coronary syndrome, irrespective of estimated risk, prior to or within 72 hours of ED discharge.<sup>2</sup> However, several 95 large observational studies of ED patients with follow-up periods ranging from 30 to 365 days 96 have noted that NICT was only associated with improved outcomes among patients with high 97 estimated coronary risk and/or elevated serum cardiac troponin values.<sup>3-12</sup> Accordingly, newer 98 guidelines and clinical policies have recommended against the routine use of NICT for ED 99 patients at low estimated risk of acute coronary syndrome.<sup>13-15</sup> 100 However, it remains possible that there are longer-term benefits of NICT for patients at low or 101 102 intermediate risk, in part because NICT does appear to increase the likelihood of coronary revascularization in these populations.<sup>4,12,16</sup> The SCOT-HEART randomized clinical trial of CT 103 coronary angiography vs. standard care among low- to intermediate-risk patients with stable 104 105 chest pain demonstrated a reduction in rates of non-fatal myocardial infarction beginning approximately 1.5 years of follow-up, an effect that appeared driven by preventative medical 106 therapies and/or earlier coronary revascularizations.<sup>17</sup> A propensity-matched study of ED 107 108 patients who underwent NICT within 30 days after a chest pain evaluation showed a nonsignificant reduction in the composite outcome of myocardial infarction or cardiovascular 109 mortality at 1 year among the intermediate-risk group (HR 0.88, 95% CI 0.77-1.01).<sup>5</sup> Finally, an 110 111 observational study of roughly 1.5 million patients in the outpatient Canadian setting examined

#### Running Title: Non-invasive cardiac testing and two-year outcomes

112	NICT completion within 90 days of a visit for chest pain or angina and found a 25% reduction in
113	a composite outcome of unstable angina, myocardial infarction, and cardiovascular mortality
114	over a median of four years of follow-up, with statistically significant reductions in each of the
115	individual outcome constituents. <sup>18</sup> Thus, it is conceivable that risk reduction among lower-risk
116	patients is more of an incremental and gradual process than among high-risk patients.
117	To help further examine this question, we previously utilized the intrinsic variability in NICT
118	utilization that exists at both the physician and medical center level to examine associations
119	between NICT and outcomes in a quasi-experimental observational fashion by creating well-
120	balanced groups of ED patients with low, intermediate, or high referrals for NICT. 8,10,16,19,20 In
121	that study, we did not observe an association between higher NICT utilization and 60-day major
122	adverse cardiac events (MACE), though we did observe a positive association between NICT and
123	coronary revascularization, consistent with other studies. <sup>4,12</sup> We now report two-year
124	outcomes from that study population, with additional differentiation between cardiac and all-
125	cause mortality. Our hypothesis was that higher NICT utilization would be associated with
126	decreased risk of two-year MACE, particularly among patients at intermediate to high risk for
127	coronary disease.

## 128 Methods

129 Study Design and Setting

We performed a retrospective study of ED chest pain encounters between January 1, 2013, and
December 31, 2019, across 21 community EDs within Kaiser Permanente Northern California
(KPNC). KPNC is a private, non-profit integrated healthcare system that covers 4.3 million
members representing one-third of the region's population. KPNC members have been found

Running Title: Non-invasive cardiac testing and two-year outcomes

134	to be comparable to the surrounding population with respect to age, sex, race and
135	ethnicity. <sup>21,22</sup> All care facilities (emergency, outpatient, inpatient) within KPNC utilize the same
136	comprehensive integrated electronic health record (EHR; Epic, Verona, WI). In this study setting,
137	patients are randomly assigned to emergency physicians in a rotating fashion upon intake and
138	triage. The study was approved by the KPNC Institutional Review Board with a waiver of
139	informed consent.

140 Patient Selection

We included patient encounters with a chief complaint or ED diagnosis of chest pain as well as a 141 serum troponin level measurement in the ED. To capture outcomes in a consistent manner, we 142 required active membership in the health system for two years following the index visit, except 143 144 in cases of death. We excluded patients aged under 30 or over 80 years (to select for patients most likely to benefit from NICT) or if there was a cardiac troponin value above the 99<sup>th</sup> 145 percentile upper reference limit during the ED visit, an index ED diagnosis of ST-elevated 146 myocardial infarction (as initial cardiac troponin levels may be normal in these patients<sup>23</sup>), an 147 ED disposition of "expired" or "left against medical advice", an objective cardiac test performed 148 149 within the prior 6 months (exercise treadmill, myocardial perfusion, stress echo, computed tomography [CT] coronary angiography, cardiac catheterization), or if the assigned ED physician 150 had less than 100 eligible encounters for a given epoch (inadequate sampling for NICT referral 151 152 ranking, as defined below). In cases of multiple encounters by the same patient during the 153 study period, only the first study eligible ED encounter within a given two-year window was included to avoid overlapping outcome periods. 154

155 Baseline Variables

### Running Title: Non-invasive cardiac testing and two-year outcomes

156	For each patient encounter, study variables were obtained from the EHR using automated
157	electronic data extraction. This methodology was previously validated using both manually
158	abstracted and prospectively collected data, with similar levels of agreement as compared to
159	other prospective interrater data validation studies among ED chest pain patients. <sup>24,25</sup> Variables
160	included age, past medical history, peak troponin value in the ED, and both presenting
161	symptoms and electrocardiogram (ECG) findings using text string analysis of clinical notes and
162	final ECG interpretations, respectively (Methods Supplement). We retrospectively calculated a
163	history, electrocardiogram, age, risk factors, troponin (HEART) score for each eligible patient
164	encounter (intraclass correlation coefficient of 0.84 as compared to prospective data). <sup>25</sup> Since
165	patients with troponin values above the 99 <sup>th</sup> percentile were excluded from the study, the
166	maximum HEART score was 8 as opposed to 10 in the original HEART score validation study. <sup>26</sup>
167	For the history component of the HEART score (range 0-2 points), we weighted higher risk
168	symptoms (e.g., chest pressure or radiation to the arms or shoulders) against lower risk
169	symptoms (e.g., pain worse with inspiration or pain reproduced with palpation) in a
170	standardized fashion to arrive at a net balance of risk represented by the patient's symptoms. <sup>27</sup>
171	Troponin values were obtained using the Access AccuTnI assay from 2013 through July 14, 2014
172	and the Access AccuTnI+3 assay from July 15, 2014 through 2019 (both Beckman-Coulter, Brea,
173	CA). The 99 <sup>th</sup> percentile upper reference limit for both assays is 0.04 ng/mL per local
174	institutional reporting guidelines and reference literature. <sup>28</sup> Because high-normal range
175	troponins have prognostic value independent of the HEART score, we treated absolute troponin
176	value an independent risk factor categorized as either below the limit of quantitation (LOQ,
177	<0.02 ng/ml) or within the quantifiable normal range (between 0.02-0.04 ng/ml). <sup>24</sup>

Running Title: Non-invasive cardiac testing and two-year outcomes

# 178 NICT referral groups

179	As described previously <sup>16</sup> , to help account for confounding by indication, we utilized emergency
180	physician-level variation in NICT referral. This approach takes advantage of the significant
181	variance among emergency physicians in their tendency to refer for NICT and the context of a
182	random patient-to-physician assignment system used within the study setting. We ranked
183	emergency physicians based on how often their study-eligible patients were referred for NICT
184	within 72 hours of the ED encounter. This ranking was relative to other emergency physicians in
185	the local practice (to control for interfacility practice variation) and was repeated during three
186	discrete 28-month epochs of time covering the entire study period (to account for personnel
187	changes within local practices). To improve ranking accuracy, we excluded encounters if the
188	emergency physician had less than 100 study-eligible patient encounters within a given epoch.
189	Encounters were then categorized into one of three groups of NICT referral (low, intermediate,
190	high) based on the facility and epoch-specific relative ranking of the initially assigned
191	emergency physician. The distribution of baseline covariates between NICT referral groups was
192	assessed using standardized differences with a value less than 0.10 indicating acceptable
193	covariate balance. <sup>29</sup>

194 Outcomes

The primary outcome was MACE within a two-year follow-up period from the index encounter. MACE was defined as the composite of myocardial infarction, cardiac arrest, cardiogenic shock, or cardiac death. Myocardial infarction, cardiac arrest, and cardiogenic shock were defined based on the presence of corresponding International Classification of Disease, 9<sup>th</sup> and 10<sup>th</sup> revision (ICD-9/10) diagnosis codes (ICD-9 for January 1, 2013 through September 30, 2015;

### Running Title: Non-invasive cardiac testing and two-year outcomes

200	ICD-10 for October 1, 2015 through December 31, 2019) listed as the first or second diagnosis
201	at an inpatient or ED encounter within the integrated health care system, or in a coded claim
202	for services provided at a facility outside the integrated health care system. We determined
203	mortality using a composite death database drawing from KPNC mortality records, California
204	Department of Public Health Vital Records, the Social Security Death Index, and the National
205	Death Index (for cause of death). Cardiac death was designated if an ICD-10 code for "diseases
206	of the heart" (as per the National Vital Statistics System) was listed as an underlying cause of
207	death. <sup>30</sup> Secondary outcomes were coronary revascularization (percutaneous or surgical) and
208	MACE inclusive of all-cause mortality (MACE-ALL), both within a two-year follow-up period.
209	Coronary revascularization was deemed to have occurred if any corresponding ICD-9/10
210	procedure or current procedural technology (CPT) code was used during a hospitalization
211	within or outside the integrated health care system. Coronary revascularization was treated as
212	a separate outcome (as opposed to being included within the composite MACE definition)
213	because there is no reliable method to differentiate between elective or non-elective coronary
214	revascularizations using diagnostic and/or billing codes, and elective coronary revascularization
215	procedures are inconsistent with consensus agreements on appropriate composite MACE
216	definitions. <sup>31,32</sup> ICD-9/10 and CPT codes used for the outcome definitions above are detailed in
217	Methods Supplement 2. To describe downstream processes of care, we measured the following
218	within 30 days of an encounter: performance of objective cardiac testing (NICT or cardiac
219	catheterization), new prescriptions for cardiovascular medications (no prior fills from that drug
220	class in the 120 days prior) and outpatient visits with primary care physicians or cardiologists.

221 Statistical Analysis

Running Title: Non-invasive cardiac testing and two-year outcomes

222	Associations between the rate of MACE, MACE-ALL or coronary revascularization and NICT
223	referral group were assessed using mixed-effects proportional hazard models adjusted for
224	patient age, sex, individual risk factors, peak troponin in the ED, ischemic-appearing ECG, and
225	study epoch, with random effects at the facility level and robust standard errors. For MACE and
226	coronary revascularization, we determined the cause-specific hazard by censoring for
227	competing outcomes (non-cardiac death for MACE and all-cause mortality for coronary
228	revascularization). <sup>33</sup> The low referral group served as the reference category. These models
229	were applied both to the overall study population and separately to patients within the three
230	strata of HEART score (low-risk = 0-3; moderate-risk = 4-6; high-risk = > 6). An $\alpha$ =0.05 was used
231	to define statistical significance of hypothesis tests, with p-values adjusted for multiple
232	comparisons using the Holm-Bonferroni method. <sup>34</sup> Data analyses were performed using Stata
233	17.0 (StataCorp, TX).

234 Sensitivity Analysis

235 Since previous findings showed a general decline in the completion of objective cardiac testing within 30 days of the index ED visit during the third study epoch<sup>35</sup>, and to account for potential 236 impact of the COVID-19 pandemic on two-year follow-up period<sup>36</sup>, we repeated the overall 237 statistical analysis using encounters from only the first and second study epochs (January 1, 238 2013 through August 31, 2017). We also repeated the primary analysis among a restricted 239 240 subgroup of encounters with troponin values in the guantifiable range of normal (0.02 to 0.04 241 ng/ml) due to the higher independent risk of MACE in these patients, as noted above. Given that proportional hazards do not indicate the magnitude of association between a covariate 242 and a dependent variable<sup>37</sup>, we alternatively examined the association between NICT referral 243

244	group and two-year MACE-ALL using mixed-effects logistic regression. Finally, as a post-hoc
245	exploratory analysis, we assessed for interactions between the high and low NICT referral
246	groups and several covariates (age, known coronary artery disease, HEART risk score category,
247	and peak troponin value).
248	Results
249	There were 144,577 included ED encounters (Figure 1) with 700 emergency physicians across
250	the 7-year study period. HEART score distribution was 48.2% low-risk, 49.2% moderate-risk and
251	2.7% high-risk. The median age was 58 years (interquartile range 48-68 years), 57% were
252	female, 23% had diabetes, 13% had coronary artery disease, 3.9% had ischemic ECG findings,
253	12% had a peak troponin between the LOQ and the 99 <sup>th</sup> percentile, and 20% were referred for
254	NICT within 72 hours of the ED encounter (Table 1). Baseline demographic and risk factors were
255	well-balanced across NICT referral groups, and the frequency of NICT referral was significantly
256	different between low, intermediate, and high groups (13.0%, 19.9%, and 27.8%, p<0.0001,
257	Table 1). Covariate balance was maintained within HEART score risk strata with similar
258	between-group differences in NICT referral (Table S1).
259	Unadjusted downstream 30-day processes of care and two-year outcomes are presented in
260	Table 2. Higher NICT referral was associated with higher 30-day objective cardiac testing (53.0%
261	versus 32.8% in high versus low groups) along with small increases in new cardiovascular
262	medication prescriptions and outpatient visits with either primary care or cardiology. Overall
263	observed MACE and MACE-ALL within two years was 4.8% and 7.7%, respectively. On adjusted
264	survival analyses (Table 3), neither intermediate or high NICT referral were associated with a
265	lower adjusted hazard ratio (aHR) for MACE (aHRs of 1.08 and 1.05, respectively) or MACE-ALL

### Running Title: Non-invasive cardiac testing and two-year outcomes

266	(aHRs of 1.06 and 1.04, respectively), with lower bounded 95% confidence intervals between
267	0.99 and 1.02. Analysis by HEART score risk strata revealed similar differences between NICT
268	groups in 30-day objective cardiac testing (Table S2), but likewise no evidence of lower adjusted
269	hazards of MACE or MACE-ALL between NICT referral groups within any of the three HEART
270	score risk strata (Table 4). There were likewise no statistically significant differences in
271	coronary revascularizations in any of the above analyses.
272	Sensitivity analyses excluding encounters from the third study epoch (Table S3), restricted to
273	patients with quantifiable peak troponins (Table S4), or using mixed-effects logistic regression
274	for the MACE-ALL outcome (Table S5) were consistent with the primary analysis. Post-hoc
275	exploratory analysis restricted to the low and high NICT referral groups demonstrated
276	statistically significant interactions between NICT referral group and age (p = 0.012), HEART risk
277	score category (p = 0.032) and peak troponin level (p = 0.027), though in no instance was higher
278	NICT referral significantly associated with a lower hazard of MACE (Figure 2). Unadjusted
279	Kaplan-Meier curves for MACE-ALL are demonstrated in Figure 3.
280	Discussion
281	The 2021 American Heart Association/American College of Cardiology chest pain evaluation
282	guideline recommends against the urgent use of NICT in low-risk ED patients with chest pain,
283	stating that "there is no evidence that stress testing or cardiac imaging within 30 days of the
284	index ED visit improves their outcomes". <sup>38</sup> Since this recommendation was based on studies
285	which used follow-up periods between 30 and 365 days <sup>4,6-8,10-12,27,39,40</sup> , we sought to assess
286	whether increased use of NICT might improve outcomes out to two years, specifically among
287	ED patients without objective evidence of myocardial injury. Despite finding that 1 in 5

### Running Title: Non-invasive cardiac testing and two-year outcomes

288	additional patients underwent objective cardiac testing within 30 days in the high NICT referral
289	group (equating to approximately 10,000 additional patients, as compared to the low NICT
290	referral group), we did not find that increased NICT referral was associated with a decrease in
291	the hazard of two-year MACE or MACE-ALL. While the magnitude of effect of a covariate on an
292	outcome cannot be directly inferred from proportional hazard model coefficients <sup>37</sup> , the lower
293	bounded aHR 95% confidence intervals for MACE and MACE-ALL (0.99 to 1.02) make it unlikely
294	that an inverse relationship exists between NICT referral and these outcomes, lending further
295	support to the above recommendation.
296	The 2021 guideline also recommends further functional or anatomic cardiac testing for most
297	patients at intermediate risk, defined as patients who do not meet low-risk criteria but have no
298	evidence of acute myocardial injury by troponin testing, criteria that represent 52% of our study
299	cohort. However, we did not observe any evidence that higher NICT referral reduced the
300	hazard of MACE among moderate-risk patients (HEART score 4 to 6) despite similar between-
301	group differences in 30-day objective cardiac testing and a higher incidence of two-year MACE
302	(7.2% versus 4.8% in the whole cohort). While findings were also null for higher-risk patients
303	(HEART score > 6 or quantifiable troponin measurements), both smaller sample sizes and less
304	pronounced between-group differences in 30-day objective cardiac testing render those results
305	more susceptible to a type 1 error, and thus less interpretable. We likewise did not observe any
306	overall differences in coronary revascularizations with higher NICT referral, in contrast to our
307	prior study of 60-day outcomes in this population but consistent with other longer-term studies
308	of NICT. <sup>16,17</sup> This may be attributable to a general decline in the performance of coronary

309 revascularizations in the US over the past 20 years, as well as evidence suggesting equipoise

Running Title: Non-invasive cardiac testing and two-year outcomes

310 between percutaneous coronary interventions and optimal medical therapy in patients with

311 chronic coronary syndromes.<sup>41-43</sup>

While our findings differ from those of Roifmen et al.<sup>5</sup> and Kawatakar et al.<sup>7</sup>, both of which 312 313 reported some degree of reduction in MACE following NICT amongst high-risk ED patients with chest pain, there are some notable differences in study designs. Roifmen et al. matched on the 314 propensity to have undergone NICT, rather than intent to refer for NICT, while Kawatkar et al. 315 employed an instrumental variable approach (medical center-level variation in NICT 316 317 performance and day-of-the week presentation). Both of these strategies are subject to 318 residual confounding from factors associated with both NICT completion and outcomes, 319 including access to care, health literacy, functional capacity, and treatment adherence, as well as MACE that preempt NICT completion.<sup>44-46</sup> In contrast, by using *referral* for NICT as an 320 indicator of practice variation at the individual physician level, the current study is more 321 322 representative of an intention-to-treat design and avoids the potential for attrition bias when 323 examining at the level of NICT and/or objective cardiac test completion. To be clear, these findings do not indicate that patients without evidence of acute myocardial 324 injury do not benefit from NICT, but rather that accepted determinants of clinical risk (such as 325 the HEART score and its components) may not be ideally suited to identifying which patients 326 might benefit. This is suggested by our post-hoc exploratory analysis where we observed an 327 interaction between NICT group (low or high) and age, with patients aged 30 to 49 years 328 329 bordering on a reduced hazard of MACE with high NICT referral (aHR 0.81, 95% CI 0.65-1.00). 330 On the surface, this appears counterintuitive since this age group is largely comprised of lowrisk patients (median age was 49 years in low-risk HEART score subgroup versus 65 years in the 331

### Running Title: Non-invasive cardiac testing and two-year outcomes

332	moderate-risk subgroup). However, it is also apparent that traditional cardiac risk factors carry
333	greater prognostic weight in younger patients such that effective risk factor modification (such
334	as smoking cessation), perhaps spurred on by greater referral for NICT, could have greater
335	proportional benefits in younger individuals. <sup>47-50</sup> But, given the low overall event rates among
336	younger patients, well targeted approaches to identifying patients with occult and/or
337	premature coronary artery disease are needed. <sup>51</sup>
338	The mode of NICT employed may also be an important determinant of potential benefit. Of the
339	NICTs performed in our study, approximately one-third had an imaging component (myocardial
340	perfusion, stress echocardiography or CT coronary angiography). The SCOT-HEART study, an
341	open-label randomized controlled trial of 4146 patients with stable chest pain, compared CT
342	coronary angiography to usual care and found significantly lower rates of mortality and
343	myocardial infarction beginning at around 2 years among those randomized to the
344	intervention. <sup>40,52</sup> The CATCH trial, a randomized controlled trial of 576 patients with acute-
345	onset chest pain and both normal ECGs and serial cardiac troponins, compared a CT coronary
346	angiography-guided treatment strategy to standard care with a functional NICT and found that
347	CT coronary angiography reduced downstream MACE out to a median of 19 months, though
348	the difference in myocardial infarction or cardiac death was not statistically significant (p =
349	0.06). <sup>53</sup> In contrast, the PROMSIE trial, which randomized 10,003 symptomatic outpatients
350	without established coronary artery disease to either anatomic testing with CT coronary
351	angiography or functional NICT, did not demonstrate any difference in clinical outcomes out to
352	a median of two years. <sup>54</sup> Whether patient selection for (and potential benefit from) CT
353	coronary angiography can be further tailored with the use of high-sensitivity cardiac troponin

## Running Title: Non-invasive cardiac testing and two-year outcomes

354	assays (specifically among patients with mildly elevated but non-diagnostic high-sensitivity
355	troponin values) is being addressed through the ongoing TARGET-CTCA study (NCT03952351).
356	Thus, while the utility of routine and/or urgent functional NICT in low- and intermediate-risk ED
357	patients has rightly been questioned, in large part due to low testing yields <sup>55,56</sup> , there may still
358	yet be a role for anatomic NICT in mitigating long-term risks in selected patients.
359	This study has several limitations. All included patients were insured and cared for within an
360	integrated health care system, which may have reduced overall outcome risks and somewhat
361	limits generalizability. Given the observational study design, we cannot infer a causal
362	relationship between NICT referral and outcomes, especially regarding any suggestion of an
363	increased hazard of MACE and MACE-ALL with higher NICT referral, though it is plausible that
364	higher NICT referral was associated with delayed diagnoses and treatment of alternative life-
365	threatening conditions owing to anchoring bias. <sup>57</sup> Though residual baseline confounding is
366	possible, there were no observed imbalances in measured patient-level variables typically
367	associated with NICT referral (e.g. age, risk factors, HEART score) and all study patients had
368	active health plan insurance coverage and were grouped at the medical-center level over
369	discrete epochs of time, making systematic differences in access to NICT between groups highly
370	unlikely. Since our study excluded patients with troponin measurements above the 99 <sup>th</sup>
371	percentile of normal, our results should not be extrapolated to this specific higher risk patient
372	population in whom benefits of NICT are more likely. <sup>7</sup> Finally, in terms of study power, though
373	no formal calculations were performed given the fixed study period and uncertainty
374	surrounding the ranges of NICT referral variation, the largest statistically significant result in
375	terms of adjusted hazards (aHR 1.08 for MACE in the intermediate versus low NICT referral

Running Title: Non-invasive cardiac testing and two-year outcomes

376	group, adjusted p value = 0.024) correlated to a 0.4% unadjusted absolute increase in two-year
377	MACE between these groups. This finding suggests that the analysis was highly sensitive to
378	clinically relevant differences in outcomes, with the caveat for smaller high-risk subgroups
379	noted above.
380	Conclusion
381	In this large observational study evaluating the association between 72-hour NICT referral and
382	two-year outcomes following ED chest pain encounters in which acute myocardial injury had
383	been excluded, higher NICT referral was not associated with a decreased risk of MACE. These
384	findings suggest that routine NICT referral does not improve cardiac outcomes for most ED
385	patients without evidence of acute myocardial injury, though the impact among the higher risk
386	subset of patients remains unclear. Further studies in more targeted populations (using high-
387	sensitivity troponin values) and/or using specific testing modalities (e.g. CT coronary
388	angiography) may further inform best practices.
389	Acknowledgments: None.
390	Sources of Funding: This project was supported by The Permanente Medical Group's Delivery
391	Science and Applied Research program.
392	Disclosures: None.
393	Supplemental Material: Supplemental Methods, Tables S1-S5
394	References
395	1. National Hospital Ambulatory Medical Care Survey: 2017 Emergency Department Summary

396 Tables. <u>https://www.cdc.gov/nchs/data/nhamcs/web\_tables/2017\_ed\_web\_tables-508.pdf</u>.
397 Accessed January 9th.

398	2.	Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr., Ganiats TG, Holmes DR, Jr., Jaffe AS, Jneid
399		H, Kelly RF, Kontos MC, et al. 2014 AHA/ACC Guideline for the Management of Patients with
400		Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of
401		Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the
402		American College of Cardiology. 2014;64:e139-228. doi: 10.1016/j.jacc.2014.09.017
	2	
403	3.	Kini V, Dayoub EJ, Hess PL, Marzec LN, Masoudi FA, Ho PM, Groeneveld PW. Clinical Outcomes
404		After Cardiac Stress Testing Among US Patients Younger Than 65 Years. Journal of the American
405		Heart Association. 2018;7:e007854. doi: 10.1161/JAHA.117.007854
406	4.	Foy AJ, Liu G, Davidson WR, Jr., Sciamanna C, Leslie DL. Comparative effectiveness of diagnostic
407		testing strategies in emergency department patients with chest pain: an analysis of downstream
408		testing, interventions, and outcomes. JAMA internal medicine. 2015;175:428-436. doi:
409		10.1001/jamainternmed.2014.7657
410	5.	Roifman I, Han L, Koh M, Wijeysundera HC, Austin PC, Douglas PS, Ko DT. Clinical Effectiveness
	J.	
411		of Cardiac Noninvasive Diagnostic Testing in Patients Discharged From the Emergency
412		Department for Chest Pain. Journal of the American Heart Association. 2019;8:e013824. doi:
413		10.1161/JAHA.119.013824
414	6.	Safavi KC, Li SX, Dharmarajan K, Venkatesh AK, Strait KM, Lin H, Lowe TJ, Fazel R, Nallamothu BK,
415		Krumholz HM. Hospital variation in the use of noninvasive cardiac imaging and its association
416		with downstream testing, interventions, and outcomes. JAMA internal medicine. 2014;174:546-
417		553. doi: 10.1001/jamainternmed.2013.14407
418	7.	Kawatkar AA, Sharp AL, Baecker AS, Natsui S, Redberg RF, Lee MS, Ferencik M, Wu YL, Shen E,
419		Zheng C, et al. Early Noninvasive Cardiac Testing After Emergency Department Evaluation for
420		Suspected Acute Coronary Syndrome. JAMA internal medicine. 2020;180:1621-1629. doi:
421	0	10.1001/jamainternmed.2020.4325
422	8.	Roifman I, Han L, Koh M, Wijeysundera HC, Austin PC, Douglas PS, Ko DT. Use of Cardiac
423		Noninvasive Testing After Emergency Department Discharge: Association of Hospital Network
424		Testing Intensity and Outcomes in Ontario, Canada. Journal of the American Heart Association.
425		2020;9:e017330. doi: 10.1161/JAHA.120.017330
426	9.	Natsui S, Sun BC, Shen E, Redberg RF, Ferencik M, Lee MS, Musigdilok V, Wu YL, Zheng C,
427		Kawatkar AA, et al. Higher Emergency Physician Chest Pain Hospitalization Rates Do Not Lead to
428		Improved Patient Outcomes. Circulation Cardiovascular quality and outcomes.
429		2021;14:e006297. doi: 10.1161/CIRCOUTCOMES.119.006297
430	10.	Natsui S, Sun BC, Shen E, Wu YL, Redberg RF, Lee MS, Ferencik M, Zheng C, Kawatkar AA, Gould
431	10.	MK, et al. Evaluation of Outpatient Cardiac Stress Testing After Emergency Department
432		Encounters for Suspected Acute Coronary Syndrome. <i>Annals of emergency medicine</i> .
433		2019;74:216-223. doi: 10.1016/j.annemergmed.2019.01.027
434	11.	Meyer MC, Mooney RP, Sekera AK. A critical pathway for patients with acute chest pain and low
435		risk for short-term adverse cardiac events: role of outpatient stress testing. Annals of emergency
436		<i>medicine</i> . 2006;47:427-435. doi: 10.1016/j.annemergmed.2005.10.010
437	12.	Sandhu AT, Heidenreich PA, Bhattacharya J, Bundorf MK. Cardiovascular Testing and Clinical
438		Outcomes in Emergency Department Patients With Chest Pain. JAMA internal medicine.
439		2017;177:1175-1182. doi: 10.1001/jamainternmed.2017.2432
440	13.	American College of Emergency Physicians Clinical Policies Subcommittee on Suspected Non
441	13.	STEACS, Tomaszewski CA, Nestler D, Shah KH, Sudhir A, Brown MD. Clinical Policy: Critical Issues
442		in the Evaluation and Management of Emergency Department Patients With Suspected Non-ST-
443		Elevation Acute Coronary Syndromes. <i>Annals of emergency medicine</i> . 2018;72:e65-e106. doi:
444		10.1016/j.annemergmed.2018.07.045

Running Title: Non-invasive cardiac testing and two-year outcomes

445 14. Musey PI, Jr., Bellolio F, Upadhye S, Chang AM, Diercks DB, Gottlieb M, Hess EP, Kontos MC, 446 Mumma BE, Probst MA, et al. Guidelines for reasonable and appropriate care in the emergency 447 department (GRACE): Recurrent, low-risk chest pain in the emergency department. Academic 448 emergency medicine : official journal of the Society for Academic Emergency Medicine. 449 2021;28:718-744. doi: 10.1111/acem.14296 450 15. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, 451 Bullock-Palmer RP, Conejo T, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for 452 the Evaluation and Diagnosis of Chest Pain: A Report of the American College of 453 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 454 Circulation. 2021;144:e368-e454. doi: 10.1161/CIR.0000000000001029 455 16. Mark DG, Shan J, Huang J, Ballard DW, Vinson DR, Kene MV, Sax DR, Rauchwerger AS, Reed ME, 456 Kaiser Permanente CNI. Higher intensity of 72-h noninvasive cardiac test referral does not 457 improve short-term outcomes among emergency department patients with chest pain. 458 Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 459 2022;29:736-747. doi: 10.1111/acem.14448 460 17. Investigators S-H, Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M, Forbes J, 461 Hunter A, Lewis S, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. The 462 New England journal of medicine. 2018;379:924-933. doi: 10.1056/NEJMoa1805971 463 18. Roifman I, Sivaswamy A, Chu A, Austin PC, Ko DT, Douglas PS, Wijeysundera HC. Clinical 464 Effectiveness of Cardiac Noninvasive Diagnostic Testing in Outpatients Evaluated for Stable 465 Coronary Artery Disease. Journal of the American Heart Association. 2020;9:e015724. doi: 466 10.1161/JAHA.119.015724 467 19. Cotterill PG, Deb P, Shrank WH, Pines JM. Variation in chest pain emergency department admission rates and acute myocardial infarction and death within 30 days in the Medicare 468 469 population. Academic emergency medicine : official journal of the Society for Academic 470 Emergency Medicine. 2015;22:955-964. doi: 10.1111/acem.12728 471 20. Roifman I, Han L, Fang J, Chu A, Austin P, Ko DT, Douglas P, Wijeysundera H. Patient, physician 472 and geographic predictors of cardiac stress testing strategy in Ontario, Canada: a population-473 based study. BMJ Open. 2022;12:e059199. doi: 10.1136/bmjopen-2021-059199 474 21. Gordon N, Lin T. The Kaiser Permanente Northern California Adult Member Health Survey. Perm 475 J. 2016;20:15-225. doi: 10.7812/TPP/15-225 476 22. Davis AC, Voelkel JL, Remmers CL, Adams JL, McGlynn EA. Comparing Kaiser Permanente 477 Members to the General Population: Implications for Generalizability of Research. Perm J. 478 2023;27:87-98. doi: 10.7812/TPP/22.172 479 23. Wereski R, Chapman AR, Lee KK, Smith SW, Lowe DJ, Gray A, Mills NL. High-Sensitivity Cardiac 480 Troponin Concentrations at Presentation in Patients With ST-Segment Elevation Myocardial 481 Infarction. JAMA Cardiol. 2020;5:1302-1304. doi: 10.1001/jamacardio.2020.2867 482 24. Mark DG, Huang J, Chettipally U, Kene MV, Anderson ML, Hess EP, Ballard DW, Vinson DR, Reed 483 ME, Kaiser Permanente CNI. Performance of Coronary Risk Scores Among Patients With Chest 484 Pain in the Emergency Department. Journal of the American College of Cardiology. 2018;71:606-485 616. doi: 10.1016/j.jacc.2017.11.064 486 25. Mark DG, Huang J, Kene MV, Sax DR, Cotton DM, Lin JS, Bouvet SC, Chettipally UK, Anderson ML, 487 McLachlan ID, et al. Automated Retrospective Calculation of the EDACS and HEART Scores in a 488 Multicenter Prospective Cohort of Emergency Department Chest Pain Patients. Academic 489 emergency medicine : official journal of the Society for Academic Emergency Medicine. 490 2020;27:1028-1038. doi: 10.1111/acem.14068 491 26. Backus BE, Six AJ, Kelder JC, Bosschaert MA, Mast EG, Mosterd A, Veldkamp RF, Wardeh AJ, Tio 492 R, Braam R, et al. A prospective validation of the HEART score for chest pain patients at the

493		emergency department. International journal of cardiology. 2013;168:2153-2158. doi:
494		10.1016/j.ijcard.2013.01.255
495	27.	Mahler SA, Lenoir KM, Wells BJ, Burke GL, Duncan PW, Case LD, Herrington DM, Diaz-Garelli JF,
496		Futrell WM, Hiestand BC, et al. Safely Identifying Emergency Department Patients With Acute
497		Chest Pain for Early Discharge. Circulation. 2018;138:2456-2468. doi:
498		10.1161/CIRCULATIONAHA.118.036528
499	28.	Greene DN, Leong TK, Collinson PO, Kamer SM, Huang K, Lorey TS, Go AS. Age, sex, and racial
500		influences on the Beckman Coulter AccuTnI+3 99th percentile. Clinica chimica acta;
501		international journal of clinical chemistry. 2015;444:149-153. doi: 10.1016/j.cca.2015.02.005
502	29.	Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between
503		treatment groups in propensity-score matched samples. Statistics in medicine. 2009;28:3083-
504		3107. doi: 10.1002/sim.3697
505	30.	National Center for Health Statistics, Centers for Disease Control and Prevention. National Vital
506		Statistics System: instructions for classification of underlying and multiple causes of death—
507		2023 https://www.cdc.gov/nchs/nvss/manuals/2023/2a-2023.htm. 2023. Accessed June 6th.
508	31.	Cullen L, Than M, Brown AF, Richards M, Parsonage W, Flaws D, Hollander JE, Christenson RH,
509		Kline JA, Goodacre S, et al. Comprehensive standardized data definitions for acute coronary
510		syndrome research in emergency departments in Australasia. Emergency medicine Australasia :
511		EMA. 2010;22:35-55. doi: 10.1111/j.1742-6723.2010.01256.x
512	32.	Derington CG, Heath LJ, Kao DP, Delate T. Validation of algorithms to identify elective
513		percutaneous coronary interventions in administrative databases. <i>PloS one</i> . 2020;15:e0231100.
514		doi: 10.1371/journal.pone.0231100
515	33.	Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of
516		Competing Risks. Circulation. 2016;133:601-609. doi: 10.1161/CIRCULATIONAHA.115.017719
517	34.	Holm S. A Simple Sequentially Rejective Multiple Test Procedure. Scandinavian Journal of
518		Statistics. 1979;6:65-70.
519	35.	Mark DG, Huang J, Ballard DW, Kene MV, Sax DR, Chettipally UK, Lin JS, Bouvet SC, Cotton DM,
520		Anderson ML, et al. Graded Coronary Risk Stratification for Emergency Department Patients
521		With Chest Pain: A Controlled Cohort Study. Journal of the American Heart Association.
522		2021:e022539. doi: 10.1161/JAHA.121.022539
523	36.	Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung SH, Ambrosy AP, Sidney S, Go AS. The
524		Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction. The New England journal
525		of medicine. 2020;383:691-693. doi: 10.1056/NEJMc2015630
526	37.	Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for
527		competing risk data. Statistics in medicine. 2017;36:4391-4400. doi: 10.1002/sim.7501
528	38.	Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J,
529		Bullock-Palmer RP, Conejo T, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for
530		the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American
531		College of Cardiology/American Heart Association Joint Committee on Clinical Practice
532		Guidelines. Circulation. 2021:CIR00000000000001030. doi: 10.1161/CIR.00000000000001030
533	39.	Reinhardt SW, Lin CJ, Novak E, Brown DL. Noninvasive Cardiac Testing vs Clinical Evaluation
534		Alone in Acute Chest Pain: A Secondary Analysis of the ROMICAT-II Randomized Clinical Trial.
535		JAMA internal medicine. 2018;178:212-219. doi: 10.1001/jamainternmed.2017.7360
536	40.	Scot-Heart Investigators. CT coronary angiography in patients with suspected angina due to
537		coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet.
538		2015;385:2383-2391. doi: 10.1016/S0140-6736(15)60291-4
539	41.	Soares A, Boden WE, Hueb W, Brooks MM, Vlachos HEA, O'Fee K, Hardi A, Brown DL. Death and
540		Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in

541		Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Meta-Analysis
542		of Contemporary Randomized Controlled Trials. Journal of the American Heart Association.
543		2021;10:e019114. doi: 10.1161/JAHA.120.019114
544	42.	Galli M, Benenati S, Zito A, Capodanno D, Zoccai GB, Ortega-Paz L, Iaconelli A, D'Amario D, Porto
545		I, Burzotta F, et al. Revascularization strategies versus optimal medical therapy in chronic
546		coronary syndrome: A network meta-analysis. International journal of cardiology. 2023;370:58-
547		64. doi: 10.1016/j.ijcard.2022.10.023
548	43.	Kataruka A, Maynard CC, Kearney KE, Mahmoud A, Bell S, Doll JA, McCabe JM, Bryson C, Gurm
549		HS, Jneid H, et al. Temporal Trends in Percutaneous Coronary Intervention and Coronary Artery
550		Bypass Grafting: Insights From the Washington Cardiac Care Outcomes Assessment Program.
551		Journal of the American Heart Association. 2020;9:e015317. doi: 10.1161/JAHA.119.015317
552	44.	Du L, Cheng Z, Zhang Y, Li Y, Mei D. The impact of medication adherence on clinical outcomes of
553		coronary artery disease: A meta-analysis. European journal of preventive cardiology.
554		2017;24:962-970. doi: 10.1177/2047487317695628
555	45.	Tang WH, Topol EJ, Fan Y, Wu Y, Cho L, Stevenson C, Ellis SG, Hazen SL. Prognostic value of
556		estimated functional capacity incremental to cardiac biomarkers in stable cardiac patients.
557		Journal of the American Heart Association. 2014;3:e000960. doi: 10.1161/JAHA.114.000960
558	46.	Magnani JW, Mujahid MS, Aronow HD, Cene CW, Dickson VV, Havranek E, Morgenstern LB,
559		Paasche-Orlow MK, Pollak A, Willey JZ, et al. Health Literacy and Cardiovascular Disease:
560		Fundamental Relevance to Primary and Secondary Prevention: A Scientific Statement From the
561		American Heart Association. Circulation. 2018;138:e48-e74. doi:
562		10.1161/CIR.000000000000579
563	47.	Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D.
564		Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.
565		<i>Circulation</i> . 2006;113:791-798. doi: 10.1161/CIRCULATIONAHA.105.548206
566	48.	Kaneko H, Yano Y, Okada A, Itoh H, Suzuki Y, Yokota I, Morita K, Fujiu K, Michihata N, Jo T, et al.
567		Age-Dependent Association Between Modifiable Risk Factors and Incident Cardiovascular
568		Disease. Journal of the American Heart Association. 2023;12:e027684. doi:
569		10.1161/JAHA.122.027684
570	49.	Yandrapalli S, Nabors C, Goyal A, Aronow WS, Frishman WH. Modifiable Risk Factors in Young
571		Adults With First Myocardial Infarction. Journal of the American College of Cardiology.
572		2019;73:573-584. doi: 10.1016/j.jacc.2018.10.084
573	50.	Age dependent associations of risk factors with heart failure: pooled population based cohort
574		study. BMJ. 2021;373:n880. doi: 10.1136/bmj.n880
575	51.	Michos ED, Choi AD. Coronary Artery Disease in Young Adults: A Hard Lesson But a Good
576		Teacher. Journal of the American College of Cardiology. 2019;74:1879-1882. doi:
577		10.1016/j.jacc.2019.08.1023
578	52.	Scot-Heart Investigators, Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M,
579		Forbes J, Hunter A, Lewis S, et al. Coronary CT Angiography and 5-Year Risk of Myocardial
580		Infarction. The New England journal of medicine. 2018;379:924-933. doi:
581		10.1056/NEJMoa1805971
582	53.	Linde JJ, Hove JD, Sorgaard M, Kelbaek H, Jensen GB, Kuhl JT, Hindso L, Kober L, Nielsen WB,
583		Kofoed KF. Long-Term Clinical Impact of Coronary CT Angiography in Patients With Recent
584		Acute-Onset Chest Pain: The Randomized Controlled CATCH Trial. JACC Cardiovascular imaging.
585		2015;8:1404-1413. doi: 10.1016/j.jcmg.2015.07.015
586	54.	Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ,
587		Fordyce CB, Huang M, et al. Outcomes of anatomical versus functional testing for coronary

588		artery disease. The New England journal of medicine. 2015;372:1291-1300. doi:
589 590	55.	10.1056/NEJMoa1415516 Greenslade JH, Parsonage W, Ho A, Scott A, Dalton E, Hammett C, Brown AF, Parker K, Cullen L.
591		Utility of Routine Exercise Stress Testing among Intermediate Risk Chest Pain Patients Attending
592 593	56.	an Emergency Department. <i>Heart Lung Circ</i> . 2015;24:879-884. doi: 10.1016/j.hlc.2015.03.025 Rahman F, Mitra B, Cameron PA, Coleridge J. Stress testing before discharge is not required for
594		patients with low and intermediate risk of acute coronary syndrome after emergency
595		department short stay assessment. <i>Emergency medicine Australasia : EMA</i> . 2010;22:449-456. doi: 10.1111/j.1742-6723.2010.01331.x
596 597	57.	Ly DP, Shekelle PG, Song Z. Evidence for Anchoring Bias During Physician Decision-Making. JAMA
598		internal medicine. 2023. doi: 10.1001/jamainternmed.2023.2366
599		
600		
601		
602		
603		
005		
604		
605		
606		
607		
007		
608		
609		
610		
611		
011		
612		

Running Title: Non-invasive cardiac testing and two-year outcomes

# 613 Table 1. Cohort characteristics.

	All	Low NICT referral	Intermediate NICT referral	High NICT referral	Std. Diff. (Interm. vs low)	Std. Diff. (High vs low)
Number of patients	144,577	45,773	50,048	48,756		
Characteristics		ſ	I		1	
Age in years, median (IQR)	58 (48-68)	58 (48-68)	58 (48-68)	58 (48-68)	0.024	0.0159
Female (%)	56.7	56.7	56.5	56.7	-0.005	-0.000
Race/ethnicity (%)						
White	52.8	52.8	53.1	52.6	0.006	-0.003
Black	10.7	10.6	10.9	10.6	0.011	-0.001
Hispanic	19.5	19.7	19.1	19.5	-0.015	-0.005
Asian	15.3	15.3	15.1	15.6	-0.005	0.009
Other	1.8	1.7	1.8	1.8	0.008	0.004
Diabetes mellitus (%)	23.4	23.2	23.4	23.5	0.005	0.007
Hypertension (%)	48.2	47.9	48.4	48.3	0.010	0.008
Hypercholesteremia (%)	50.8	50.2	51.2	51.0	0.019	0.016
Obesity (BMI <u>&gt;</u> 30, %)	43.4	43.4	43.3	43.4	-0.000	-0.001
Family history of premature CAD (%)	5.7	5.4	5.7	5.9	0.010	0.019
Smoking (%)	10.0	10.0	10.0	10.0	0.002	0.001
Peripheral artery disease (%)	2.3	2.2	2.3	2.3	0.007	0.009
Cerebrovascular disease (%)	6.5	6.7	6.5	6.4	-0.007	-0.011
Myocardial infarction (%)	7.9	7.8	7.9	8.0	0.004	0.006
Coronary revascularization (%)	7.8	7.7	7.9	7.8	0.008	0.004
Coronary artery disease (%)	12.7	12.5	12.7	12.7	0.008	0.007
Peak troponin between LOQ and 99 <sup>th</sup> percentile (%)	11.9	11.6	12.0	12.2	0.012	0.019
Ischemic-appearing ECG (%)	3.9	3.9	3.9	4.0	-0.001	0.004
HEART score, median (IQR)	4 (2-5)	4 (2-5)	4 (2-5)	4 (2-5)	0.026	0.037
HEART score 0-3 (low risk, %)	48.2	49.1	48.0	47.4	-0.021	0.034
HEART score 4-6 (moderate risk, %)	49.2	48.4	49.3	49.7	0.018	0.026
HEART score > 6 (high risk, %)	2.7	2.5	2.6	2.8	0.010	0.024
Processes						
NICT referral within 72 hours (%)	20.4	13.0	19.9	27.8	0.186	0.374
Index hospital admission (%)	6.1	5.7	6.3	6.4	0.027	0.031
ED LOS, hours (median, IQR)	3.8 (2.6- 5.5)	3.6 (2.5- 5.1)	3.9 (2.6-5.5)	4.1 (2.7- 5.7)	0.109	0.201
Serial troponin testing (%)	35.4	29.7	35.6	40.6	0.126	0.231

Running Title: Non-invasive cardiac testing and two-year outcomes

- Patient encounters were categorized into low, intermediate, or high NICT referral groups based
- on the ranking of the initial treating emergency physician within their primary medical center
- and during the epoch corresponding to the encounter. A standardized difference less than 0.1
- 618 indicates adequate balance of a given variable between groups.
- 619 Abbreviations: BMI = body mass index; CAD = coronary artery disease; ECG =
- 620 electrocardiogram; HEART = history, electrocardiogram, age, risk factors, troponin; IQR =
- 621 interquartile range; LOQ = limit of quantitation; LOS = length of stay; NICT = non-invasive
- 622 cardiac test.

Running Title: Non-invasive cardiac testing and two-year outcomes

# **Table 2.** Unadjusted 2-year outcomes and 30-day cardiac testing by non-invasive cardiac test

645 (NICT) referral group.

		Low NICT	Intermediate	High NICT	p-
	All	referral	NICT referral	referral	value
Number of patients	144,577	45,773	50,048	48,756	
2-year outcomes (%)					
Acute myocardial infarction	3.4	3.2	3.6	3.5	0.0042
Cardiac arrest	0.5	0.6	0.5	0.5	0.5070
Cardiogenic shock	0.2	0.2	0.3	0.2	0.2663
Coronary revascularization	2.8	2.7	2.8	2.9	0.1395
Cardiac mortality	1.3	1.3	1.3	1.2	0.2539
All-cause mortality	4.6	4.5	4.7	4.5	0.2375
MACE	4.8	4.6	5.0	4.8	0.0102
MACE-ALL	7.7	7.4	7.9	7.8	0.0148
30-day mediators (%)					
Objective cardiac testing	43.2	32.8	43.0	53.0	<.0001
Exercise treadmill	34.2	25.9	34.1	42.1	<.0001
Myocardial perfusion	11.3	8.1	11.3	14.3	<.0001
Stress echocardiography	0.7	0.6	0.7	0.9	0.0005
CT coronary angiography	0.5	0.4	0.5	0.6	0.0005
Cardiac catheterization	3.9	3.6	3.8	4.1	<.0001
Outpatient follow-up	55.3	53.6	55.5	56.7	<.0001
Primary care	52.6	51.1	52.8	53.8	<.0001
Cardiology	7.3	6.7	7.3	7.8	<.0001
New cardiovascular medication prescription	10.3	9.6	10.3	10.8	<.0001
ACE inhibitor or ARB	3.1	3.1	3.1	3.2	0.2014
Antiplatelet	2.8	2.5	2.7	3.3	<.0001
Beta-blocker	4.4	4.1	4.6	4.6	0.0002
Statin	3.5	3.4	3.5	3.6	0.1845

646

647 Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; CT =

648 computed tomography; ECG = electrocardiography; MACE = major adverse cardiac event;

649 MACE-ALL = major adverse cardiac event, including all-cause mortality; NICT = non-invasive 650 cardiac test.

651

652

653

....

Running Title: Non-invasive cardiac testing and two-year outcomes

- **Table 3.** Adjusted hazards of primary and secondary outcomes according to non-invasive
- 656 cardiac test (NICT) referral group.

Outcome	NICT referral group	Adjusted hazard ratio (95% CI)	P-value	Adjusted p-value*
	Low	1.0 (ref)	n/a	n/a
2-year MACE	Intermediate	1.08 (1.02-1.14)	0.012	0.024
	High	1.05 (0.99-1.11)	0.13	0.13
	Low	1.0 (ref)	n/a	n/a
2-year MACE- ALL	Intermediate	1.06 (1.01-1.10)	0.023	0.046
	High	1.04 (0.99-1.09)	0.13	0.13
	Low	1.0 (ref)	n/a	n/a
2-year coronary revascularization	Intermediate	1.03 (0.96-1.11)	0.43	0.43
	High	1.07 (0.99-1.15)	0.10	0.20

657

Associations between outcomes and NICT referral group were assessed using mixed-effects

659 proportional hazard models adjusting for patient age, sex, risk factors (diabetes, coronary

artery disease, coronary revascularization, smoking, hypertension, hypercholesteremia, obesity,

661 family history of premature coronary artery disease), peak troponin value while the emergency

department, ischemic-appearing changes on electrocardiogram, and epoch, with censoring of

663 competing outcomes (non-cardiac death for MACE, all-cause mortality for coronary

revascularization), random effects at the facility level, and robust standard errors.

665 \* Holm-Bonferroni method

- 666 Abbreviations: MACE = major adverse cardiac event; MACE-ALL = major adverse cardiac event, 667 including all-cause mortality; NICT = non-invasive cardiac test.
- 660
- 668
- 669
- 670
- 671
- 672
- 673

Running Title: Non-invasive cardiac testing and two-year outcomes

- **Table 4.** Adjusted primary and secondary outcomes by non-invasive cardiac test (NICT) referral
- 675 group, stratified by HEART score.

	NICT referral	Adjusted hazard ratio		Adjusted
Outcome	group	(95% CI)	P-value	p-value*
		scores (0 to 3, n = 69639	))	p toto
	Low	1.0 (ref)	n/a	n/a
2-year MACE	Intermediate	1.06 (0.90-1.24)	0.49	0.98
,	High	0.91 (0.78-1.08)	0.29	0.88
	Low	1.0 (ref)	n/a	n/a
2-year MACE-ALL	Intermediate	1.01 (0.91-1.12)	0.91	1.0
	High	0.93 (0.84-1.04)	0.21	0.84
2	Low	1.0 (ref)	n/a	n/a
2-year coronary revascularization	Intermediate	1.06 (0.85-1.31)	0.61	1.0
revascularization	High	0.97 (0.77-1.21)	0.77	1.0
	Moderate-risk HEA	RT scores (4 to 6, n = 71	108)	
	Low	1.0 (ref)	n/a	n/a
2-year MACE	Intermediate	1.10 (1.02-1.17)	0.009	0.054
	High	1.08 (1.01-1.16)	0.021	0.11
	Low	1.0 (ref)	n/a	n/a
2-year MACE-ALL	Intermediate	1.07 (1.01-1.13)	0.017	0.10
	High	1.06 (1.01-1.12)	0.028	0.14
2 year coronary	Low	1.0 (ref)	n/a	n/a
2-year coronary revascularization	Intermediate	1.02 (0.93-1.12)	0.66	1.0
Tevascularization	High	1.09 (0.99-1.19)	0.071	0.43
	High-risk HEAI	RT scores (> 6, n = 3830)		_
	Low	1.0 (ref)	n/a	n/a
2-year MACE	Intermediate	0.99 (0.84-1.17)	0.93	0.98
	High	0.90 (0.76-1.06)	0.22	0.88
	Low	1.0 (ref)	n/a	n/a
2-year MACE-ALL	Intermediate	1.04 (0.90-1.21)	0.58	1.0
	High	0.98 (0.84-1.13)	0.75	1.0
	Low	1.0 (ref)	n/a	n/a
2-year coronary revascularization	Intermediate	1.05 (0.86-1.28)	0.64	1.0
	High	0.94 (0.77-1.15)	0.55	1.0

676

677

Following stratification into HEART score risk categories (0 to 3 = low risk; 4 to 6 = moderate

risk; > 6 = high risk), associations between outcomes and NICT referral group were assessed

using mixed effects proportional hazard models adjusting for patient age, sex, risk factors


681 (diabetes, coronary artery disease, coronary revascularization, smoking, hypertension,

- 682 hypercholesteremia, obesity, family history of premature coronary artery disease), peak
- 683 troponin value while the emergency department, ischemic-appearing changes on
- electrocardiogram, and epoch, with censoring of competing outcomes (non-cardiac death for
- 685 MACE, all-cause mortality for coronary revascularization), random effects at the facility level,
- 686 and robust standard errors.
- <sup>687</sup> \* Holm-Bonferroni method for multiple comparisons within and between categories
- 688 Abbreviations: CV = cardiovascular; HEART = history, electrocardiogram, age, risk factors,
- 689 troponin; MACE = major adverse cardiac event; MACE-ALL = major adverse cardiac event,
- 690 including all-cause mortality; NICT = non-invasive cardiac test.

691			
692			
693			
694			
695			
696			
697			
698			
699			
700			
701			
702			
703			
704			

Running Title: Non-invasive cardiac testing and two-year outcomes

# 705 Figure 1. Cohort selection.



\*To account for practice pattern changes due to time as a confounder in our ranking of ED

provider NICT referral-intensity, we divided the 7-year study period into three equal (28-month)
 epochs: 1) January 1, 2013 through April 30, 2015; 2) May 1, 2015 through August 31, 2017; 3)

730 September 1, 2017 through December 31, 2019.

731 Abbreviations: ED = emergency department; HEART = history, electrocardiogram, age, risk

732 factors, troponin; KPNC = Kaiser Permanente Northern California; STEMI = ST-elevated


733 myocardial infarction.

Running Title: Non-invasive cardiac testing and two-year outcomes

#### Figure 2. Forest plot of post-hoc exploratory interaction analyses for major adverse cardiac 734

#### events (MACE): high versus low non-invasive cardiac test (NICT) referral group. 735

736



737

Cause-specific mixed-effects proportional hazard models for MACE were run with an interaction 738

739 term of NICT (high versus low) and each variable of interest (age, coronary artery disease,

740 HEART risk score, peak troponin level) respectively, adjusting for other covariates with random

effect at facility level and censoring for non-cardiac death. 741

Abbreviations: Adj = adjusted; HEART = history, electrocardiogram, age, risk factors, troponin; 742

743 LOQ = limit of quantitation; MACE = major adverse cardiac event; NICT = non-invasive cardiac test.

744

745

746

747


748

749

750

Running Title: Non-invasive cardiac testing and two-year outcomes





753

754 Unadjusted incidence of MACE-ALL within two years according to non-invasive cardiac test

755 (NICT) referral group.

756 MACE-ALL = major adverse cardiac event, inclusive of all-cause mortality; NICT = non-invasive

757 cardiac test